IPO - Enliven Therapeutics, Inc.

Form Type: 424B5

Filing Date: 2025-06-16

Corporate Action: Ipo

Type: New

Accession Number: 000119312525140928

Filing Summary: Enliven Therapeutics, Inc. is conducting an initial public offering (IPO) of 8,394,737 shares of its common stock along with pre-funded warrants to purchase 1,780,263 additional shares. The offering price per share is set at $19.66, with pre-funded warrants priced slightly lower at $19.659. Each pre-funded warrant allows investors to purchase one share at an exercise price of $0.001. The IPO proceeds are expected to total approximately $200 million before expenses, with roughly $188 million projected to flow to the company. The common stock is listed on the Nasdaq Global Select Market under the symbol "ELVN." Following this IPO, the company may issue an additional 1,526,250 shares if underwriters exercise their options. Delivery of the securities is expected on June 16, 2025. The prospectus indicates that Enliven is pursuing a strategic plan with a focus on its lead product candidate ELVN-001, aimed at treating chronic myeloid leukemia (CML), and intends to explore strategic alternatives for another candidate, ELVN-002, which it does not plan to develop beyond 2025. The document warns investors about various risks associated with the investment, including the company's status as an emerging growth company with reduced reporting requirements, and the complexities of the ongoing clinical trials.

Form Type: 8-K

Filing Date: 2025-06-16

Corporate Action: Ipo

Type: New

Accession Number: 000119312525141085

Filing Summary: On June 13, 2025, Enliven Therapeutics, Inc. entered into an underwriting agreement for a public offering of 9,920,987 shares of common stock at $19.66 per share. The offering includes 1,526,250 shares from the underwriters’ option to purchase additional shares and 1,780,263 pre-funded warrants. Proceeds from the offering are expected to be around $216.1 million after deductions. The closing date is expected on June 16, 2025, subject to customary conditions. The offering is made under the effective registration statements on Form S-3.